AEE788 | NVP-AEE 788 | EGFR/ErbB2 Inhibitor | AmBeed-信号通路专用抑制剂

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

产品名称	EGFR/ErbB1 ↓ ↑	ErbB3 ↓ ↑	ErbB4 ↓ ↑	HER2/ErbB2 ↓ ↑	mutant EGFR ↓ ↑	其他靶点	纯度
WZ-3146	++++ EGFR (E746_A750), IC50: 2 nM EGFR (E746_A750/T790M), IC50: 14 nM						99%+
Daphnetin	+ EGFR, IC50: 7.67 μM					PKA,PKC	95%
Lifirafenib	++ EGFR, IC50: 29 nM				+ EGFR(T790M/L858R), IC50: 495 nM		98%
PD168393	++++ EGFR, IC50: 0.70 nM						99%+
Nazartinib	++ mutant EGFR, Ki: 0.031 μM				++ mutant EGFR, Ki: 0.031 μM		98%
Norcantharidin	✔						98%
CL-387785	++++ EGFR, IC50: 370 pM						98%
WHI-P154	+++ EGFR, IC50: 4 nM					Src,VEGFR	98%
Tyrphostin A9	+ EGFR, IC50: 460 μM					PDGFR	98%
AG 555	+ EGFR, IC50: 0.7 μM						98%
AG 494	+ EGFR, IC50: 1.2 μM						99%+
AG-556	+ EGFR, IC50: 5 μM						98%
RG13022	+ EGFR, IC50: 4 μM						99%+
Tyrphostin RG 14620	✔						99%+
Vandetanib	+ EGFR, IC50: 500 nM						99%
CNX-2006	++ mutant EGFR, IC50: <20 nM				++ mutant EGFR, IC50: <20 nM		99%
AZD3759	++++ EGFR (L858R), IC50: 0.2 nM EGFR (WT), IC50: 0.3 nM						98%
Erlotinib	++++ EGFR, IC50: 2 nM						95%
Saracatinib	+++ EGFR (L861Q), IC50: 4 nM EGFR, IC50: 5 nM						99%+
AG1557	✔						99%
Rociletinib	++ EGFR (L858R/T790M), Ki: 21.5 nM EGFR (wt), Ki: 303.3 nM						98%
AG490	+ EGFR, IC50: 0.1 μM						98%
Cetuximab	++++ EGFR, Kd: 0.39 nM						95%
Osimertinib	++ WT EGFR, IC50: 12.92 nM L858R/T790M EGFR, IC50: 11.44 nM						98%
Osimertinib mesylate	✔						98% (Content MsOH 15.2-18.2%)
Chrysophanol	✔					mTOR	98%
PD153035	++++ EGFR, Ki: 5.2 pM						99%+
Olmutinib	✔					BTK	99%+
WZ4002	++++ EGFR (L858R/T790M), IC50: 8 nM EGFR (L858R), IC50: 2 nM						99%+
Icotinib	+++ EGFR, IC50: 5 nM						99%
Desmethyl Erlotinib HCl	++++ EGFR, IC50: 2 nM						98%
Cyasterone	✔						99%+
PP 3	+ EGFR tyrosine kinase, IC50: 2.7 μM						98%
WZ8040	✔						99%+
(-)-Epigallocatechin Gallate	✔						99%
AG 18	+ EGFR, IC50: 35 μM						99%+
O-Desmethyl gefitinib	++ EGFR, IC50: 36 nM						99%
Falnidamol	✔						99%+
AZ-5104	++++ EGFR (L858R), IC50: 6 nM EGFR (L861Q) , IC50: <1 nM		+++ ErbB4, IC50: 7 nM			BRK	99%+
Butein	✔						95%
Genistein	✔						98%
SU5214	+ EGFR, IC50: 36.7 μM						99%+
Naquotinib	✔						99%+
Gefitinib	++ EGFR, IC50: 15.5 nM				+ EGFR (858R/T790M), IC50: 823.3 nM		98%
Theliatinib	+++ WT EGFR, IC50: 3 nM				++ EGFR T790M/L858R, IC50: 22 nM		99%
Lazertinib	++++ WT EGFR, IC50: 76 nM L858R/T790M EGFR, IC50: 2 nM				++++ Del19/T790M, IC50: 1.7 nM		99%+
Gefitinib-based PROTAC 3	++ EGFR, DC50: 22.3 nM						99%+
MTX-211	✔					PI3K	98%
(E)-AG 99	✔						99%+
Licochalcone D	✔					PARP,Caspase	99%
Zipalertinib	+++ EGFR WT, IC50: 8 nM EGFR (L861Q), IC50: 4.1 nM		+++ HER4, IC50: 4 nM		++++ EGFR(d746-750), IC50: 1.4 nM EGFR L858R, IC50: 2 nM		97%
JND3229	+++ EGFR WT, IC50: 6.8 nM				++ EGFR L858R/T790M, IC50: 30.5 nM		99%+
Firmonertinib mesylate	✔						99%+
Tyrphostin AG30	✔						99%+
EGFR-IN-12	++ EGFR, IC50: 21 nM						99%+
Mobocertinib	✔						98%
(Rac)-JBJ-04-125-02	✔						95%
(S)-Sunvozertinib	✔						99%
BLU-945	✔						95%
Poziotinib	+++ HER1, IC50: 3.2 nM		++ HER4, IC50: 23.5 nM	+++ HER2, IC50: 5.3 nM			98%
TAK-285	++ EGFR/HER1, IC50: 23 nM		+ HER4, IC50: 260 nM	++ HER2, IC50: 17 nM			99%+
ARRY-380 analog				✔			99%
Canertinib	++++ EGFR, IC50: 1.5 nM			+++ ErbB2, IC50: 9.0 nM			99%+
Dacomitinib	+++ EGFR, IC50: 6.0 nM		+ ErbB4, IC50: 73.7 nM	+ ErbB2, IC50: 45.7 nM			98%
EGFR/ErbB-2/ErbB-4 inhibitor-2			+ ErbB4, IC50: 1.91 μM	+ ErbB2, IC50: 0.08 μM			99%+
(E/Z)-CP-724714				++ HER2/ErbB2, IC50: 10 nM			95%
Lapatinib	++ EGFR, IC50: 10.8 nM		+ ErbB4, IC50: 367 nM	+++ ErbB2, IC50: 9.2 nM			98%
AEE788	++++ EGFR, IC50: 2 nM		+ HER4/ErbB4, IC50: 160 nM	+++ HER2/ErbB2, IC50: 6 nM		c-Fms/CSF1R	98+%
AV-412 free base	++++ EGFR, IC50: 0.75 nM			++ ErbB2, IC50: 19 nM	++++ EGFR^L858R/T790M, IC50: 0.51 nM EGFR^T790M, IC50: 0.79 nM		98+%
Neratinib	+ EGFR, IC50: 92 nM			+ HER2, IC50: 59 nM		Src	98%
BMS-599626	++ HER1, IC50: 20 nM		+ HER4, IC50: 190 nM	++ HER2, IC50: 30 nM			98%
Tucatinib				+++ ErbB2, IC50: 8 nM			98%
Allitinib	++++ EGFR, IC50: 0.5 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			99%
Pelitinib	+ EGFR, IC50: 38.5 nM			+ ErbB2, IC50: 1.255 μM		Src,Raf	99%+
Sapitinib	+++ EGFR, IC50: 4 nM	+++ ErbB3, IC50: 4 nM		+++ ErbB2, IC50: 3 nM			99%+
CUDC-101	+++ EGFR, IC50: 2.4 nM			++ HER2, IC50: 15.7 nM		HDAC	99%+
Varlitinib	+++ ErbB1, IC50: 7 nM			++++ ErbB2, IC50: 2 nM			99%+
Afatinib dimaleate	++++ EGFR (L858R/T790M), IC50: 0.4 nM EGFR (wt), IC50: 0.5 nM			++ HER2, IC50: 14 nM			98%
Canertinib 2HCl	+++ EGFR, IC50: 7.4 nM			+++ ErbB2, IC50: 9 nM			99%
Allitinib tosylate	++++ EGFR (T790M/L858R), IC50: 12 nM EGFR, IC50: 0.5 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			99%
Tyrphostin AG 528	+ EGFR, IC50: 4.9 μM			+ HER2, IC50: 2.1 μM			97%
Afatinib	++++ EGFR (wt), IC50: 0.5 nM EGFR (L858R), IC50: 10 nM		++++ ErbB4, IC50: 1 nM	++ HER2, IC50: 14 nM			99%
Pyrotinib dimaleate	++ EGFR, IC50: 0.013 μM			++ HER2, IC50: 0.038 μM			98%
Epertinib HCl	++++ EGFR, IC50: 1.48 nM		+++ HER4, IC50: 2.49 nM	+++ HER2, IC50: 7.15 nM			99%
Tuxobertinib	++++ EGFR, Kd: 0.2 nM			++++ HER2, Kd: 0.76 nM			99%
ALK-IN-1					++ EGFR(del19), IC50: 36.8 nM EGFR(C797S/del19), IC50: 138.6 nM	ALK	99%
Brigatinib					+ EGFR(C797S/T790M/del19), IC50: 67.2 nM EGFR(del19), IC50: 39.9 nM	ALK,FLT3	98%
Avitinib					++++ EGFR L858R/T790M, IC50: 0.18 nM	BTK	99%+
EAI045					✔		97%
Almonertinib					✔		99%
BI-4020					++++ EGFR^{del19 T790M C797S}, IC50: 0.2 nM		99%+
EGFR-IN-7					++++ EGFR^L858R/T790M, IC50: 0.19 nM EGFR^{d746-750/T790M/C797S}, IC50: 0.26 nM		99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	HER2 ↓ ↑	其他靶点	纯度
Poziotinib	++++ HER2, IC50: 5.3 nM		98%
Tyrphostin AG 879	+ HER2-Neu, IC50: 1.0 μM		95%
TAK-285	+ HER2, IC50: 17 nM		99%+
ARRY-380 analog	✔		99%
Canertinib	+++ ErbB2, IC50: 9.0 nM	EGFR	99%+
(E/Z)-CP-724714	++ HER2/ErbB2, IC50: 10 nM		95%
Lapatinib	+++ ErbB2, IC50: 9.2 nM	EGFR	98%
AEE788	++++ HER2/ErbB2, IC50: 6 nM	EGFR	98+%
Neratinib	+ HER2, IC50: 59 nM	Src,EGFR	98%
BMS-599626	+ HER2, IC50: 30 nM		98%
Mubritinib	++++ HER2/ErbB2, IC50: 6.0 nM		99%+
Tucatinib	+++ ErbB2, IC50: 8 nM		98%
Sapitinib	++++ ErbB2, IC50: 3 nM	EGFR	99%+
CUDC-101	++ HER2, IC50: 15.7 nM	EGFR,HDAC	99%+
Afatinib dimaleate	++ HER2, IC50: 14 nM		98%
Afatinib	++ HER2, IC50: 14 nM		99%
Pertuzumab	✔		95%
Trastuzumab	✔		99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Cell Line Hep3B cells HepG2 cells Huh-7 cells L3.6pl human pancreatic cancer cells mouse mesenteric lymphatic endothelial cells 67NR cells BT474 A3 MCF-7 A2	Concentration	Treated Time	Description	References
Hep3B cells	10 μM	72 h	To evaluate the effect of AEE788 on Hep3B cell viability, results showed that after 72 hours, 10 μM AEE788 reduced cell viability up to 85%.	Gastroenterology. 2008 Dec;135(6):1972-83, 1983. e1-11
HepG2 cells	10 μM	72 h	To evaluate the effect of AEE788 on HepG2 cell viability, results showed that after 72 hours, 10 μM AEE788 reduced cell viability up to 85%.	Gastroenterology. 2008 Dec;135(6):1972-83, 1983. e1-11
Huh-7 cells	10 μM	72 h	To evaluate the effect of AEE788 on Huh-7 cell viability, results showed that after 72 hours, 10 μM AEE788 reduced cell viability up to 85%.	Gastroenterology. 2008 Dec;135(6):1972-83, 1983. e1-11
L3.6pl human pancreatic cancer cells	20 mM		AEE788 inhibited phosphorylation of EGFR and VEGFR, reducing proliferation and inducing apoptosis in tumor cells and tumor-associated endothelial cells.	Neoplasia. 2005 Jul;7(7):696-704
mouse mesenteric lymphatic endothelial cells	0.25, 0.5, 1.0, 2.5, 5.0 μM	120 min	AEE788 inhibited Akt and ERK1/2 phosphorylation, reducing migration, proliferation, and survival of lymphatic endothelial cells	Neoplasia. 2006 Sep;8(9):747-57
67NR cells	1 μM	1 hour	To test the effect of AEE788 on ErbB receptor activity, results showed that AEE788 could block ErbB receptor activity.	Breast Cancer Res. 2013 Jan 23;15(1):R8.
BT474 A3	0.25 μM	6 days	AEE788 in combination with endocrine therapy showed significant synergistic anti-proliferative effects in ER-positive cell lines, markedly reducing IC50 values.	Br J Cancer. 2010 Apr 13;102(8):1235-43
MCF-7 A2	2 μM	6 days	AEE788 in combination with endocrine therapy showed synergistic anti-proliferative effects in ER-positive cell lines, reducing IC50 values.	Br J Cancer. 2010 Apr 13;102(8):1235-43

Species NU/NU mice Nude mice Nude mice BALB/c mice Athymic nude mice Ncr Foxhead nude mice	Animal Model Huh7 xenograft model Orthotopic human pancreatic cancer L3.6pl cell model Orthotopic HT29 human colon cancer model 4T1 and 67NR mammary tumor models Orthotopic human pancreatic cancer model ZR75.1 A3 xenograft model	Administration	Dosage	Frequency	Description	References
NU/NU mice	Huh7 xenograft model	Oral gavage	25 mg/kg	3 times/week until euthanasia	To evaluate the anti-tumoral effect of AEE788 in the Huh7 xenograft model, results showed that AEE788 significantly delayed tumor growth and increased survival.	Gastroenterology. 2008 Dec;135(6):1972-83, 1983. e1-11
Nude mice	Orthotopic human pancreatic cancer L3.6pl cell model	Oral gavage	50 mg/kg	Three times per week for 5 weeks	AEE788 alone or in combination with gemcitabine significantly inhibited tumor growth, reduced microvascular density, and induced apoptosis in tumor cells and tumor-associated endothelial cells.	Neoplasia. 2005 Jul;7(7):696-704
Nude mice	Orthotopic HT29 human colon cancer model	Oral gavage	50 mg/kg	Thrice a week for 36 days	AEE788 significantly reduced peritumoral lymphatic vessel density and incidence of lymph node metastasis	Neoplasia. 2006 Sep;8(9):747-57
BALB/c mice	4T1 and 67NR mammary tumor models	Oral	50 mg/kg	Three times per week for 12 days	To test the effect of AEE788 alone or in combination with dovitinib on tumor growth and metastasis, results showed that the combination significantly inhibited tumor growth and metastasis.	Breast Cancer Res. 2013 Jan 23;15(1):R8.
Athymic nude mice	Orthotopic human pancreatic cancer model	Oral gavage	50 mg/kg	3 times per week for 4 weeks	AEE788 alone or in combination with STI571 and gemcitabine significantly inhibited tumor growth and prolonged survival. AEE788 inhibited phosphorylation of EGFR and VEGFR, reduced tumor cell proliferation and microvascular density, and increased apoptosis in tumor cells and tumor-associated endothelial cells.	Cancer Res. 2005 Nov 15;65(22):10371-80
Ncr Foxhead nude mice	ZR75.1 A3 xenograft model	Oral gavage	6.7 mg/ml	Once daily for 24 days	To evaluate the inhibitory effect of AEE788 alone or in combination with tamoxifen or letrozole on tumor growth. Results showed that letrozole alone was more effective than tamoxifen, and AEE788 combined with letrozole showed a significantly greater inhibition of tumor growth at early time points.	Br J Cancer. 2010 Apr 13;102(8):1235-43

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00116376	Glioblastoma Multiforme	Phase 1 Phase 2	Completed	-	United States, California ... 展开 >> University of California at Los Angeles Los Angeles, California, United States, 90095 University of California, San Francisco San Francisco, California, United States, 94143 United States, North Carolina The Brain Tumor Center at Duke, Duke University Medical Center Box 3624 DUMC, Trent Drive, Durham, North Carolina, United States, 27710 United States, Texas University of Texas, MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00118456	Cancer	Phase 1	Completed	-	United States, Connecticut ... 展开 >> Yale Cancer Center New Haven, Connecticut, United States, 06520 United States, Nevada Nevada Cancer Institute Las Vegas, Nevada, United States, 89125 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77054 Institute of Drug Development/Cancer Therapy and Research Center San Antonio, Texas, United States, 78229 收起 <<
NCT00107237	Brain and Central Nervous Syst... 展开 >>em Tumors 收起 <<	Phase 1 Phase 2	Completed	-	United States, California ... 展开 >> Jonsson Comprehensive Cancer Center at UCLA Los Angeles, California, United States, 90095-1781 United States, North Carolina Duke Univaersity Medical Center Durham, North Carolina, United States, 27710 United States, Texas MD Anderson Cancer Center/University of Texas Houston, Texas, United States, 77030 收起 <<

CAS号	497839-62-0
分子式	C₂₇H₃₂N₆
分子量	440.58
SMILES Code	C[C@@H](NC1=C2C(NC(C3=CC=C(CN4CCN(CC)CC4)C=C3)=C2)=NC=N1)C5=CC=CC=C5
MDL No.	MFCD11100351

别名	NVP-AEE 788
运输	蓝冰
InChI Key	OONFNUWBHFSNBT-HXUWFJFHSA-N
Pubchem ID	10297043

AEE788 {[allProObj[0].p_purity_real_show]}

AEE788 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

AEE788 质控信息

AEE788 生物活性

AEE788 细胞实验

AEE788 动物实验

AEE788 动物研究

AEE788 临床研究

AEE788 参考文献

AEE788 实验方案

AEE788 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

EGFR/ErbB1	EGFR, IC50:2 nM
HER2/ErbB2	HER2/ErbB2, IC50:6 nM
ErbB4	HER4/ErbB4, IC50:160 nM
VEGFR1	FLT1, IC50:59 nM
VEGFR2	KDR, IC50:77 nM
HER2	HER2/ErbB2, IC50:6 nM

Huh7		Cytotoxicity assay		Cytotoxicity against human hepatocellular carcinoma cell line (Huh7), CC50=27.83 Μm	18579783
Jeko B cells		Function assay	2 h	Inhibition of PI3Kdelta in human Jeko B cells assessed as inhibition of Akt phosphorylation after 2 hrs, IC50=0.017 μM	25514658

AEE788 {[allProObj[0].p_purity_real_show]}

AEE788 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

AEE788 质控信息

AEE788 生物活性

AEE788 细胞实验

AEE788 动物实验

AEE788 动物研究

AEE788 临床研究

AEE788 参考文献

AEE788 实验方案

AEE788 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

AEE788 纯度/质量文件产品仅供科研